Phase
Condition
Hepatic Fibrosis
Scar Tissue
Hyponatremia
Treatment
CPMX2
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
In- and outpatients with liver cirrhosis of any etiology, diagnosed by either liverhistology or compatible biochemical, imaging and clinical parameters, being treatedat the department of Visceral Surgery and Medicine at Inselspital Bern, UniversityHospital Bern, Switzerland.
Age ≥ 18 years
Indication for IV albumin infusion according to current EASL guidelines[11] andBAVENO VII consensus recommendations[12] including large volume paracentesis,spontaneous bacterial peritonitis (SBP), AKI with/without HRS.
Available transthoracic echocardiography assessing right heart function withinmaximum 3 months from study inclusion.
Exclusion
Exclusion Criteria:
Patients admitted to intermediate care unit or intensive care unit at the time ofalbumin infusion
Previous IV albumin infusion within the last 5 days
Contraindication to the PLR test (i.e. increased intracranial pressure)
Contraindication to albumin infusion (i.e. anaphylactic reactions against albumin)
History of right heart failure
Clinical evidence of lung edema, hemodynamic instability/shock
Anatomic IVC abnormalities, such as IVC stenosis and/or thrombosis
History of orthotopic liver transplant
Patients unable to provide informed consent
Study Design
Study Description
Connect with a study center
University Hospital Bern
Bern, 3010
SwitzerlandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.